Dr. Jorge Carrillo obtained his degree in Biological
Sciences from the University of Córdoba (Spain) in 2000. In 2001 he joined Dr.
Verdaguer’s group at the Immunobiology Laboratory for Research and Diagnostic
Applications (LIRAD-BST) in Badalona. In 2009, he joined the IrsiCaixa
Institute for AIDS Research. In 2015, he
was appointed associate researcher in IrsiCaixa, and in May 2020 he was
designated as senior principal investigator creating the Immunology Group (IgG)
at IrsiCaixa. In addition, he is working as Chief Scientific Officer (CSO) in
AlbaJuna Therapeutic, an IrsiCaixa’s spin-off focused on the development of
broadly neutralizing proteins against HIV-1 to be used in cure strategies. His
skills and expertise mainly include HIV, Virus, Immunology of Infectious
Diseases, Viral Immunology, Vaccination, Immunization, Innate Immunity,
Antibodies, Adaptive Immunity, and Immunity.
Dr. Jorge Carrillo obtained his degree in Biological
Sciences from the University of Córdoba (Spain) in 2000. In 2001 he joined Dr.
Verdaguer’s group at the Immunobiology Laboratory for Research and Diagnostic
Applications (LIRAD-BST) in Badalona. In 2009, he joined the IrsiCaixa
Institute for AIDS Research. In 2015, he
was appointed associate researcher in IrsiCaixa, and in May 2020 he was
designated as senior principal investigator creating the Immunology Group (IgG)
at IrsiCaixa. In addition, he is working as Chief Scientific Officer (CSO) in
AlbaJuna Therapeutic, an IrsiCaixa’s spin-off focused on the development of
broadly neutralizing proteins against HIV-1 to be used in cure strategies. His
skills and expertise mainly include HIV, Virus, Immunology of Infectious
Diseases, Viral Immunology, Vaccination, Immunization, Innate Immunity,
Antibodies, Adaptive Immunity, and Immunity.